Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|January 26, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-02-03-2016
- Volume 12
- Issue 2
GS1 US Expands Advisory Services Program to Address Industry Challenges
Author(s)Pharmaceutical Technology Editors
GS1 US announces the expansion of its advisory services program to address industry needs.
Advertisement
GS1 US announced on Jan. 26, 2016 that the companies advisory services program has been expanded to address GS1 Standards implementation challenges. Launched in February 2015, GS1 Standards are widely used information standards that identify products, services, and locations to support global supply chain visibility and efficiency.
The program expansion was developed based on industry needs, including regulatory changes, omni-channel strategies, and the growing need to ensure quality data. The expanded program includes GS1 Standards implementation and education support in the following areas:
- Data quality solutions in support of the GS1 US National Data Quality Program
- Electronic Product Code (EPC) enabled radio frequency identification (RFID)
- Product images and attributes
- Unique device identification (UDI) and Drug Supply Chain Security Act (DSCSA) in the healthcare industry
- Supply chain visibility and traceability
- Global Data Synchronization Network (GDSN) implementation and Major Release 3 transitions.
According to a press announcement from GS1 US, companies with an interest in tailored support for integrating standards into their operations will receive business assessments, training, and educational materials from the company.
Source:
Articles in this issue
over 10 years ago
Is Consolidation Good for Pharma?over 10 years ago
Parenteral Packagers Focus on Security and Supply-Chain Transparencyover 10 years ago
Hermes Pharma Adds Hot Melt Coating Capabilityover 10 years ago
Novasep Adds Small-Scale Manufacturing Capability to US Facilityover 10 years ago
Vetter Completes Development and IT Facilityover 10 years ago
Adents, Siemens Team on Serialization Solutionover 10 years ago
Onyx Scientific Announces Facility Expansionover 10 years ago
FDA’s CDER Previews 2016 Guidance AgendaAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement